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Short interfering RNAs (siRNAs) are biopolymers that are used as post-transcriptional 
gene regulators and as a natural endogenous defense against attack from viruses. These 
molecules hold a great deal of interest as pharmaceuticals for the knockdown of 
unregulated genes, such as in cancers. Through chemical modification of the RNA 
structure, inherent limitations can be overcome to make better pharmaceuticals. This study 
investigated the incorporation of azobenzene derivative spacers into the RNA backbone 
replacing 2 base pairs. A small library of siRNAs were synthesized and then characterized 
bio-physically through several means. After bio-physical characterization, these siRNAs 
were tested in  vitro against firefly luciferase in order to determine gene silencing efficacy. 
The ability of these azobenzene siRNAs to be controlled with light was then investigated. 
Our results indicate that these modifications are well tolerated within the RNAi pathway 
and have a robust ability to be activated and inactivated with UV (ultraviolet) and visible 
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1.0 Introduction and Literature Review 
 
1.1 The difference between DNA and RNA 
 All of life on Earth uses the same basic building blocks in order to encode 
information that can be passed onto the next generation. These building blocks are called 
nucleotides, and they make up the genetic structure of all known living things. DNA 
(deoxyribonucleic acid) is composed of four bases, and when the four bases pair with the 
complement strand, they engage in Watson-Crick base pairing: Adenine (A), Guanine (G), 
Thymine (T) and Cytosine (C). Adenine hydrogen bonds to thymine (two hydrogen bonds) 
and    guanine    hydrogen   bonds to     cytosine  (three hydrogen bonds        forming a 
double stranded duplex.1  
 RNA (ribonucleic acid) uses three of the same bases (A, G, C) and replaces T with 
a new base, Uracil (U). In addition to the absence of thymine, RNA can have over 100 
different base modifications, as a way to expand the functionality of RNA transcripts. 
These modifications are present in all RNA types (messenger, transfer, ribosomal, small 
nuclear).2  Both DNA and RNA are sugars bound together by a phosphate backbone, the 
two biggest differences being that DNA is seldom single stranded whereas RNA often is, 
and that the RNA sugar has a 2’ hydroxyl group that is absent from DNA. Figure 1.1 shows 




Figure 1.1. Comparison of DNA and RNA structures. 
 The 2’ hydroxyl on the RNA forces a conformational change in the pucker of the 
sugar, adopting a C3’-endo conformation. This occurs because of the gauche effect (two 
vicinal functional groups separated by a torsional angle) between the 2’ OH and the 4’ 
oxygen on the sugar.3 RNA modifications such as methylation and acetylation can provide 
the cell greater flexibility in how transcripts are processed and how proteins are made. 




Figure 1.2. Natural RNA base modifications 
Many types of RNAs exist,  mRNA (messenger RNA used in translation to make proteins), 
tRNA (transfer RNA used to bring amino acids to the ribosome during protein synthesis), 
miRNA (micro RNAs which provide non-specific transcriptional control) and siRNA 
(short interfering RNA which can provide highly specific knockdown of a target mRNA).4 
Interestingly, RNAs can form structures made up of many small single stranded helices in 
order to obtain the ability to chemically catalyze reactions. These are called ribozymes and 
perform much like protein based enzymes.5 Another type of structure that can be formed 
is a G-quadruplex.6 G-quadruplexes are naturally occurring structures at the ends of 
telomeres, and consist of 4 guanine bases forming a tetrad which can then be stacked to 
form a quadruplex (Figure 1.3). They are also implicated in multiple cancers since they 
occur in transcriptional regulatory regions of oncogenes.7 These kinds of structures could 
have been partially responsible for how life started spontaneously billions of years ago, 
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groups of RNAs catalyzing reactions and becoming ever more efficient, allowing 
interactions that contributed to the building of the first cell to occur.8 
 
Figure 1.3. Left: G-tetrad. Right: G-quadruplex formed from 2 tetrads 
  One of the central tenets of molecular biology is that the translation of the 
information stored in DNA into functional molecules such as proteins is essential to all life. 
The pathway starts when genomic DNA is unwound in preparation for one of two things: 
Firstly cell division, which requires replication of the genome, and secondly, RNA 
synthesis through transcription. After the mRNA is transcribed, the polymer leaves the cell 
nucleus and is sent to the ribosome in the cytoplasm.9 The ribosome is then able through 
translation to synthesize the specific protein from the coding the mRNA contains with the 
help of tRNAs, which allow amino acids to from peptide bonds in the correct order. This 
is done through a three nucleotide code, called codons, which are specific to certain amino 
acids. Redundancies between codons/amino acids exist, and because of this the genome 
can be slightly more flexible in the case of point mutations. A single point mutation may 




 Usually process only happens in one direction, DNA to protein, but there are 
instances of the reverse occurring, where RNA can be reverse transcribed into DNA. One 
notable example is the HIV virus,11 which possesses a reverse transcriptase enzyme that 
can store its viral RNA as DNA in the host cell nucleus indefinitely, making it difficult to 
eliminate. Once it is stored in the cell’s nucleus, it can be hard to target with therapeutics 
because the nuclear membrane is also polyanionic and carrier molecules are often required 
to shuttle them across.12. There is a lot of potential and interest using siRNAs to target 
specific mRNAs, since it could be a facile way to knockdown specific gene targets with 
little to no off target effects, particularly in the fields of cancer treatment and genetic 
abnormalities. 
1.2 The RNA Interference Pathway 
 The RNA interference pathway was first observed by plant biologists who tried to 
design petunias with higher pigmentation and darker colours by adding extra copies of the 
chalcone synthase gene, an important enzyme in flower pigmentation. Instead of the 
predicted darker phenotypes, many plants instead had flowers with little or no pigment 
expressed, producing mostly white flowers. They found both the endogenous and 
transgenic genes were being suppressed.13 Further research a few years later found this 
decrease in expression was due an increase in post-transcriptional mRNA degradation 
through an unknown mechanism, and calling it “co-suppression of gene expression”.14 
Seeing this phenomenon in plants prompted the study of higher order animals to find out 
if the same mechanism could be observed. This would show that being highly conserved, 
this mRNA degradation pathway would be important to all cell types, plant and animal. 
The study of mRNA degradation continued in model organisms such as Drosophilia where 
6 
 
“co-suppression” of mRNA was first observed in animals.15  In 1998 Fire and Mello’s 
research group found that the mechanism by which the mRNA was being degraded was 
though the addition of double stranded RNA which was complementary to the mRNA 
target. This was the beginning of the modern understanding RNA interference, and they 
won the 2006 Nobel prize in physiology and medicine for this work.16 
SiRNAs are natural defense mechanisms found in the cell that are a part of the RNA 
interference pathway (RNAi). The cell uses the pathway as a defense mechanism against 
viruses or other parasites that inject dsRNA into the cells to hijack the cellular machinery 
to reproduce. They can also target specific mRNA molecules to inhibit gene expression 
after transcription by preventing the mRNA translation by the ribosome via shRNAs that 
are produced in the nucleus.17 The RNAi pathway uses an enzyme called Dicer which 
targets long double stranded RNAs (dsRNA) and cleaves them into 20-25 base pair pieces 
(siRNA). The siRNA is then unwound and the passenger strand is degraded while the guide 
strand becomes part of the RISC (RNA-induced silencing) complex, acting as a template 
for RISC to anneal to further RNA so they can be cleaved by the Argonaute 2 protein.18,19 





Figure 1.4. RNA interference pathway in humans 
  The RISC cascade can be activated through synthetic siRNAs  transfected 
into the target cells via a carrier molecule or transfection agent such as a virus,20,21 or native 
long endogenous dsRNAs can be processed by Dicer into the active RISC complex through 
cleavage at the active site. The synthetic siRNAs are often 19-22 bp long and thus bypass 
the Dicer enzyme entirely, although evidence has shown that recruitment of Dicer into the 
pathway via a 27 bp long siRNA can improve efficacy of the interference by up to ten 
times.22 The Dicer enzyme itself is composed of two RNAse III motifs, a dsRNA binding 
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domain and a RNA helicase domain which catalyzes the cleavage of the long dsRNA. In 
one example of Dicer’s importance in the RISC cascade, a Dicer knockdown study in 
human HeLa cells showed an accumulation of long dsRNAs in the cells showing an 
effective disabling of the pathway.23 
 The second part of the RISC pathway involves the endonuclease Argonaute 2 
(Ago2) which is able to catalyze the destruction of many mRNAs by removing the 
passenger strand and keeping the guide strand as a template. Ago2 is comprised of three 
domains; PAZ on the carboxyl terminus, a PIWI domain at the amino terminus and a central 
Mid section.19 The catalysis of the mRNAs is controlled by PIWI domain, and is also 
responsible for binding to the 5’ region of the antisense strand.24 Mid interacts with the 5’ 
phosphorylated end while PAZ binds to the 3’ overhang of the antisense strand.25 Knowing 
how these regions interact with each other and their mRNA substrates are incredibly 
important for designing and testing chemically modified siRNA therapeutics.26  
1.3 siRNA Therapeutic Problems 
There is a great deal of promise in using siRNAs for therapeutic research, such as 
a way to combat cancer, deadly viral infections such as Ebola, as a way to correct auto 
immune disorders or even genetic defects.27 A few issues currently exist with siRNAs, one 
is their stability as they are easily degraded, another is that an appropriate delivery system 
needs to be developed in order ensure the siRNA finds its target.28 They also have poor cell 
membrane permeability and can cause undesired off-target effects on partially homologous 
targets.  
Within all cells there are enzymes that exist solely to target and destroy nucleic 
acids, especially foreign DNA/RNA which can cause a reduction in the efficacy of nucleic 
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acid based therapeutics. These enzymes are exo/endonucleases and are prevalent in blood 
serum and in the cell’s cytoplasm which target the phosphodiester backbone of RNA.29 
The phosphodiester bond is also subject to hydrolysis at physiological pH because the 
phosphorous is oxophilic and water attacks on the electrophilic site, which is 
thermodynamically favoured.30 The oxophilic nature of the phosphorous also allows 
nucleophilic attack from the 2’ hydroxyl on the ribose in an intramolecular hydrolysis 
(Figure 1.5).31 These are the most prevalent stability issues that should be overcome to 
make an ideal therapeutic. 
Deprotonation of the phosphodiester backbone occurs at physiological pH because 
the hydroxyl group on the phosphorous has pKa of near zero.32 This gives the RNA a 
polyanionic backbone that reduces cell membrane permeability because there is a repulsion 
between the membrane, which also has a negative charge due to the phospholipid bilayer, 




Figure 1.5.  Degradation of native RNA with cleavage sites highlighted in red 
Off-target effects can also occur with siRNAs. Non-complementary base pairing 
can occur and an mRNA with a near homologous structure could be taken up into the RISC 
complex unintentionally, since mismatches can still allow the Ago2 protein to cleave its 
target.34 Another way off target effects can occur is if RISC selects the guide strand of the 
duplex to be cleaved in error, thus that Ago2 is selecting entirely the wrong targets, which 
in the best cases would show no activity and in the worst case cause apoptosis of the cell.35 
If siRNAs are going to be viable therapeutic options, these issues need to be 
overcome with some creative design of delivery systems such a nanoparticles or viral 
vectors; or chemical modifications could be used to improve the various flaws in the 
oligonucleotides. Exploration of novel chemical modifications to the siRNAs will be the 




1.4 Chemical Modifications of siRNAs 
 Organic chemists have spent years trying to mediate these disadvantages on RNA 
while keeping an appropriate amount of gene silencing activity. It matters little if the RNA 
is stable if the activity is poor. Often these modifications have their own disadvantages, 
such as being expensive, easily degraded, toxic, volatile or disrupt secondary structure and 
hydrogen bonding. Many current modifications increase stability while retaining gene 
knockdown, but no one modification seems to be able to accomplish all of these tasks 
without some kind of drawback. 
 Chemical modification of oligonucleotides using commercially available protected 
bases and DMT (dimethoxytrityl)-phosphoramidite chemical synthesis, makes adding 
normally unavailable molecules very reliable.36 In solid phase synthesis, oligos are 
synthesized one base pair at time on controlled pore glass (CPG) supports, and this is one 
of the most commonly used methods of chemical synthesis of DNA/RNA (Figure 1.6).37 
Using this method any kind of chemical modification can be incorporated into a RNA/DNA 
molecule, as long as there is an alcohol on each end of our modification that can be 





Figure 1.6. DMT-Phosphoramidite oligonucleotide solid-phase RNA synthesis. 
The CPG support can be purchased with either a dT or universal (no base) attached 
to the solid support. The synthesis proceeds in the opposite direction to biological 
synthesis, 3’→5’ direction and is entirely automated. The initial deprotection is acid 
catalyzed removal of the DMT (i) using trichloroacetic acid which affords a primary 
alcohol that can react with the 2’ phosphite of the next base in the sequence. As figure 1.6 
shows, the trityl cation is stabilized by the methoxy groups allowing for easy removal. 
Activation of the base via ethylthiotetrazole (ii) must occur before the coupling phase or 
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else no reaction will occur.39 This activation displaces the diisopropylamine group. 
Because of the oxophilic nature of the phosphorus as previously discussed, the now 
exposed primary alcohol can attack the phosphite center coupling the bases together (iii). 
RNA has phosphate linkages as opposed to phosphite ones, so oxidation must occur which 
is initiated by nucleophilic attack on the iodine (iv).  Pyridine is then used to create a 
hydroxide anion (v), which attacks the phosphorus (vi) and the resulting hydroxyl is easily 
deprotonated by another pyridine molecule creating the phosphate (vii). At this stage the 
cycle can continue to the next nucleotide to be added, or if the desired length has been 
reached the oligos can be cleaved from the solid support, deprotected and then used in 
whichever experiment was planned (viii).40 
 There are 3 kinds of chemical modifications that can be done to an oligonucleotide: 
1) Backbone substitution/addition 2) modification of the sugar directly and 3) nucleobase 
modifications. This dissertation will be concerned with modification of the phosphodiester 
backbone. 
 An example of a backbone modification is to replace one more base pairs with non-
cleavable, neutral spacers that increase the stability in vivo by replacing the phosphodiester 
linkages with something that endonucleases are unable to use as a substrate. One such 
modification is the replacement of one of the non-bonding oxygen atoms with a sulfur.41 
This phosphorothioate (PS) provides extra stability by imparting nuclease resistance.42 This 
modification however can disrupt activity when placed in or near the AGO2 cleavage site, 
since the PS substitution results in a chiral center and one of the stereoisomers is a poor 
substrate for AGO2.43 
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As the second kind of modification, sugar modifications can be as simple as adding a 
methyl group to the 2’ hydroxyl in order to eliminate self hydrolysis44 and nucleobases can 
be modified with exotic additions such a fluorine atoms, or even a fluorescent marker to 
allow for monitoring of the oligos such as 2,4-difluorotoluene (dFT)45,46 (Figure 1.7). 
 
Figure 1.7. Various chemically-modified RNA 
Even with these novel modifications, problems can arise. In order for RNAi to 
function, the siRNA must be in the A-form α helix47 and therefore modifications to the 
sugar must be done with care, especially important when trying to control the amount of 
flexibility you want your nucleotide to have. The ribose conformation can be altered 
through utilizing the gauche and anomeric effects. The favourable conformation of 
wildtype dsRNA is the C2’-endo/C2’-exo conformation, and modifications such as the 2’-
fluoro are well tolerated,48 and even provide good RNAi activity in vivo.49  
Finally, modification of the nitrogenous bases is the final path to creating a more 
stable siRNA. Since modifications here can disrupt the Watson-Crick base pairing, and 
thus distort the double helix, often substitutions are made that try to minimize the impact 
of disrupting the hydrogen bonding that occurs naturally. For example the 2,4-
diflurotoluene (dFT) is a thymine (DNA) and uracil (RNA) derivative with fluorine 
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replacing the natural oxygens50 (Figure 1.7). This provides minimal disruption to the 
normal structure when placed at the 5’ end to increase affinity to the target strand when 
placed in the guide strand. As a testament to the challenges of nucleobase modification 
however, when placed elsewhere in the sequence, a disruption of the duplex occurs as the 
dFT is unable to hydrogen bond and destabilizes the helix.51 
 As mentioned above, adding new chemical properties to the siRNAs could alter 
some of the biophysical characteristics of the duplex, the most important of which are the 
melting temperature (Tm) which is a measure of thermal stability; and the helical 
conformation which must be in the A-form to be active.52 Thermal stability is a factor 
because an unstable siRNA will dissociate at a lower temperature and thus may prove 
inactive at biological pH where many of these tests occur, since single stranded RNA is not 
a substrate for the RISC complex.53 A reduction in Tm is most often the case since most 
substitutions either distort or remove the hydrogen bonding from the base pairs.54 
 
1.5 Azobenzene and its Role in Nucleic Acid Modification 
One way to overcome these limitations is to develop a tunable controlled photo 
switchable siRNA that can be easily turned off and on with UV and visible light 
respectively. 
Azobenzene is a compound composed of two phenyl rings linked together by a 




Figure 1.8. Conformation change of azobenzene when exposed to light, trans 
(left) and cis (right) 
This molecule is of particular interest because when exposed to certain wavelengths 
of light, there is a large conformational change in the structure. The molecule can isomerize 
at the N=N bond between the trans to cis stereoisomer (Figure 1.9).56 This photo-
isomerization is also incredibly labile and robust, and maintains its efficiency after several 
isomerizations back and forth without becoming exhausted.57 The photoswitching occurs 
for trans to cis when the molecule is exposed to light in the 360 nm range, and reverse 
occurs when exposed to blue light around 430 nm. These wavelengths can be altered by 
substitutions on the ring of the molecule, so it possible to fine tune the wavelengths at 
which these isomerizations can occur.58 The thermal stability of the cis form is also 
extremely important. Azobenzene is able to thermally relax back to the trans form from cis 
just from the ambient thermal energy.59 This is especially problematic since higher 
temperatures cause the thermal relaxation to occur faster than lower temperatures, and this 
can become an issue if the experiment you are trying to run exceeds the functional half-life 
of the molecule. For example at 37 °C the half-life is about 4 hours.60 Since many biological 
assays are 24 hours long, that is about 3 half-lives and so the inactive form is becoming 





Figure 1.9. Conformational change of azobenzene trans (left ~9Å) and cis (right 
~5.5Å) when inserted into RNA 
 
Azobenzene’s unique properties have been utilized in many fields for optical 
control. One such field is liquid crystals for image storage, such as a liquid crystal display 
(LCD) in order to increase response times for better computer monitors.61 Another use is 
to control with light the rigidity of polymers.62 There is also a great deal of interest in using 
azobenzene as a control for biopolymers in vitro and in vivo in order to have some kind of 
control over various biological functions. The photoswitching aspect has been shown to be 
active in proteins, DNA and RNA as well as DNA/RNA hybrids and as a method for 
delivery via irreversible photocaging. 
In proteins, one end of the azobenzene is tethered to the protein, and at the other 
end is the ligand for the protein. The conversion to cis from trans positions the ligand 
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within the protein’s active site and “activates” it, thus turning it on.63 The protein can then 
relax back to cis normally, or a different wavelength of light can be used to turn it off. 
Another use is to use the azobenzene as a control for the secondary structure of the protein, 
such as allowing the isomerization to disrupt a helix, changing it from active to inactive or 
the reverse.64 Although the options seem limitless, one more protein related option for 
azobenzenes will be mentioned: as RET (rearranged during transfection) kinase inhibitors. 
The RET gene is located on chromosome 10 and has many natural alternative splices 
(single gene coding for many proteins). Transmembrane receptors like the RET kinase 
inhibitors (proteins which span the entire membrane to which they are permanently 
attached), such as those in neurons, are required for healthy cell function, but become 
dysfunctional in several cancers (notably thyroid) which make them a good therapeutic 
target with the on and off functionality azobenzene provides.65 Because these are 
neurotrophic receptors, it may be possible to inhibit cancer growth by stopping the 
neurotransmitters from binding by removing the receptor protein through the RNA 
interference pathway. 
Nucleic acids are also good choices for an azobenzene modification. The ability to 
control translation would be advantageous. Recent advances in this field have been made 
in controlling DNA or RNA hybridization by utilizing the azobenzene as either a 
replacement of the nitrogenous base so that the cis conformer disrupts hydrogen bonding 
and the duplex becomes unstable and separates.66 Asunama et al. has shown that 
azobenzene can be utilized as part of a threonine scaffold as a backbone replacement with 
the azobenzene intercalating among the normal bases in both cases.67 Another interesting 
use is in a hairpin at the loop position, allowing control over whether the hairpin can self-
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anneal.68 Short hairpin RNAs can activate RISC,69 and could be used as a translational 
control. An interesting study in 2015 by Wu et al. and their group showed that it was 
possible to control the activity of RNase H (exclusively targets DNA/RNA hybrids) by 
using a deoxynucleotide complement to an RNA strand, with azobenzene flanking either 
side of the active site making a dumbbell. Exposure to light would allow the RNA/DNA 
strands to anneal, and RNase H would be able to digest the hybrid.70 This kind of control 
could allow for the targeting of specific RNA sequences at specific times, by activating 
and deactivating it at will. 
Lastly work with non-reversible photo cages has also shown some advancement. A 
photo cage is a molecule or several molecules that when exposed to light either change 
shape or are cleaved entirely from the molecule.71 One such example of a small molecule 
delivery system is that of o-nitrobenzyl derivatives which when exposed to light goes 
through a intramolecular hydrogen abstraction by the nitro group forms the aci-nitro and 
goes through a rearrangement to nitroso derivatives.72 
 
Figure 1.10. o-nitrobenzyl derivative for use as a photocage 
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Utilizing these kinds of photoactive molecules it is possible to attach them to small 
molecules such as drugs,73 or enzyme substrates74 (as done by Hiraoka and Hamachi 2003) 
and have them released upon exposure to light, keeping the inactive form available until 
needed. In the case of enzyme substrates they are used to bulk the small molecule up so it 
will no longer fit inside the active site of the enzyme, and when removed activity can 
resume.75 Mikat and Heckel 2007 also showed that it is possible to control RNAi with 
photo cage materials by surrounding the mRNA cleavage site between base pairs 10 and 
11 in order to disable RNAi. Irradiation of UV light at 366 nm was shown to reactivate the 
pathway and had similar activity to the unmodified siRNAs.76 
Recent work from Dr. Jean-Paul Desaulniers’ research group has shown that 
aromatic spacer linkages77 and non-aromatic alkyl spacer linkages54 are substrates for the 
RNAi pathway when these modifications are placed within the central region of the sense 
strand. This suggests that a large aromatic group may also function at the central region 
and would make an appropriate bioactive siRNA bearing unique functionality.  Desaulniers 
et al. (2017) has shown siRNAs with biphenyl aromatic linkers did in fact have excellent 
knockdown ability targeting the endogenous BCL-2 gene.78 Additional recent work from 
his group has also revealed that large hydrophobic groups like cholesterol can cross the cell 
membrane and inhibit gene expression without a transfection carrier79 (Figure 1.8 shows 
the progression of modifications).  
This suggests that azobenzene has the potential to offer some unique advantages 
for a chemically modified siRNA. Despite this potential, siRNAs bearing azobenzene 
within the central region has not been explored. This modification could prevent localized 
off-target effects to surrounding healthy tissue, since potentially the siRNA is only being 
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activated by the light switch in the diseased tissue. Many cancer treatments employ systems 
that harm healthy tissue, such as pharmaceuticals and excision, but some healthy tissue is 
always destroyed in the process. Our azobenzene modified siRNA may be able to mitigate 
some of these disadvantages. Homologous mRNA off-target effects may still occur, 
causing undesirable phenotypes or unexpected toxicity but these are usually concentration 








Figure 1.11 Various central region modifications in siRNAs from Dr. Jean-Paul 





1.6 The Benefits of Using an Azobenzene Modification 
If this modification is incorporated into a biological molecule like siRNA, this 
conformational change could potentially allow for the controlled activation and 
inactivation of the molecule with the application of a light source. Azobenzene as a 
backbone substitution is also more stable, since enzymes that degrade RNA in the cell, 
target the natural phosphodiester backbone as their substrate, and a different molecule 
(azobenzene) in their active site is likely to show no degradation. Another benefit is that 
since it has a neutral charge, cell membrane permeability should also increase, due to less 
repulsion between the negatively charged siRNA and the cell membrane, which has a 
negative charge as well.34  
Incorporation of the photo-switchable azobenzene into a siRNA would allow 
specific genes to be targeted without having to be inside the nucleus of the cell, which can 
be difficult to get through with compounds that are not naturally occurring. It will also 
allow potentially very good spacial and temporal control over translation. Two azobenzene 
derivatives, Az1 and Az2 (Figure 1.8) were synthesized and their stability and activity was 
tested. Potential targets for these siRNAs could be the BCL-2 or BCL-3 genes involved in 
non-Hodgkins lymphoma81 or any other oncogene implicated in cancers. The genes that 
code BCL-2 and BCL-3 are anti-apoptotic proteins that control cell death. Disruption of 
this pathway prevents apoptosis through overexpression and can allow cancerous cells to 
propagate. By targeting the mRNA, we prevent the protein from forming and possibly 
mitigating or eliminating the actual effects of the mutation, without removing or disabling 
the problematic DNA. This would allow therapeutic targets to be reached more easily, since 
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only one membrane would have to be crossed in order to silence the gene of interest which 
would increase the effectiveness of the treatment. 
 
1.7 Project Definition 
 Being able to silence genes pre translation provides many avenues of treatment for 
various diseases. This promising future of siRNAs as therapeutic agents is limited only by 
the kinds of chemical modifications we can impart in order to achieve our desired 
characteristics. As this field expands, more siRNAs will be developed with better cell 
permeability, resistance to nucleases and reduced off target effects and toxicity. 
1.7.1 Objectives and Hypothesis 
Objective 1. Chemical synthesis of azobenzene and azobenzene modified siRNAs. 
constructs. 
Objective 2. Biophysical Characterization of azobenzene modified siRNAs. 
Objective 3. In vivo testing of azobenzene modified siRNAs against firefly 
luciferase in HeLa cells. 
Hypothesis: Inserting an azobenzene derivative into the siRNA backbone will 
allow tunable photochemical control of the siRNA’s activity through the use of UV 
(inactivation) and visible (reactivation) light. 
 Objective one of this project will involve the development of a small library of 
central region and 3’ end azobenzene containing siRNA oligonucleotides. As seen in 
Figure 1.8, and shown in the previous study by Desaulniers et al. (2017) the central region 
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will easily accommodate large aromatic spacers. The next step is to add functionality to the 
spacer with N=N bond, through an azobenzene moiety. The modification will be 
synthesized using organic chemistry and synthetically incorporated into RNA 
oligonucleotides. Objective two will take the azobenzene containing sense strands and 
anneal them to their complement sequence to form active siRNA duplexes. These annealed 
siRNAs will undergo hybridization testing via melting temperature assays as well testing 
of the α helix with circular dichroism to confirm the secondary structure. These bio-
physical characterizations will be tested under both visible and ultraviolet conditions in 
order to determine the activity of the photo-switch. Further bio-physical characterization 
of the siRNAs will be through absorbance spectra and how it changes, as well as HPLC 
characterizations in order to quantify the trans to cis conversions immediately and 
quantitatively. Objective three will test the siRNAs ability to silence gene expression using 
the dual luciferase reporter system from Promega. This will allow for easy quantification 
of the siRNAs knockdown ability. After gene silencing is confirmed the siRNAs will be 
treated with UV light in order to inactivate them in vivo and if successful they will then be 










2.0 Experimental Procedures 
2.1 General Methods 
Unless otherwise indicated all starting reagents used were obtained from 
commercial sources without additional purification. Anhydrous CH2Cl2 and THF were 
purchased from Sigma-Aldrich and run through a PureSolv 400 solvent purification system 
to maintain purity. Flash column chromatography was performed with Silicycle Siliaflash 
60 (230-400 mesh), using the procedure developed by Still, Kahn and Mitra.81 NMRs were 
performed on a Varian 400 MHz spectrophotometer. All 1H NMRs were recorded for 64 
transients at 400 MHz and all 13C NMRs were run for 1500 transients at 101 MHz and all 
31P NMRs were recorded for 256 transients at 167 MHz.  Spectra were processed and 















2.2 Synthesis and Characterization of Organic Compounds 
2.2.1 Synthesis of 4,4’-bis(hydroxyethyl)-azobenzene (1) 
 
(1) 
 To a solution of 90.0 mL of 5.70 M NaOH(aq) 4.00 g of 4-nitrophenethyl alcohol 
(23.9 mmol, 1.00 equiv.) was added and stirred until fully dissolved. To this solution 6.00 
g Zn powder (92.3 mmol, 3.85 equiv.) was slowly added to maintain stirring. After 
refluxing overnight for 16 h it was then filtered on a Buchner Vacuum filter, and the crystals 
were suspended in hot methanol.  The crystals were collected and filtered again with a 
gravity filter to remove residual salts and then the methanol solution was removed using a 
rotary evaporator. Crystals were collected and purified on silica gel column using MeOH 
(2% to 5%) in CH2Cl2 to afford compound 1 as orange crystals (2.34 g, 72%). 
1H NMR 
(400 MHz, d6-DMSO) δ 7.75 - 7.81 (d, J  = 8.21 Hz 4H) 7.41 (d, J  = 8.21, Hz 4H) 4.71 (t, 
J  = 5.28 Hz, 2H) 3.65 (td, J = 6.84, 5.47 Hz, 4H) 2.80 (t, J  = 6.84 Hz, 4H). 13C NMR (101 
MHz, d6-DMSO) 150.8, 144.0, 130.3, 122.7, 62.2, 38.8; ESI-HRMS (ES
+) m/z calculated 










2.2.2 Synthesis of 4-hydroxyethyl-4’-O-(4,4’dimethoxytrityl)-azobenzene  (2) 
 
(2) 
 To a solution of anhydrous of 30.0 mL of THF 1.50 g of compound 1 (5.55 mmol, 
1.00 equiv.) was added and stirred until fully dissolved. To the solution 1.95 g of 4,4’-
dimethoxytrityl chloride (5.76 mmol, 1.00 equiv.) was added along with 2.50 mL 
triethylamine (17.9 mmol, 3.00 equiv.) The reaction mixture was stirred vigorously 
overnight and monitored by TLC. The crude reaction was then concentrated by rotovap 
and purified on silica gel column using MeOH (2% to 5%) in CH2Cl2 to afford compound 
2 as an orange oil (1.11 g, 35%). 1H NMR (400 MHz, d-CDCl3)  δ 7.87 (td, J = 9.09, 1.37 
Hz, 6H) 7.45 - 7.47 (m, 2H) 7.24-7.40 (m, 3 H) 7.18 - 7.22 (m, 5H) 6.80 - 6.87(m, 4H) 
3.91(t, J = 6.45 Hz, 2H) 3.75 - 3.82(s, 6H) 3.36 (t, J = 6.64 Hz, 2H) 3.07 (s, 1H) 2.94 - 2.98 
(m, 4H). 13C NMR (101 MHz, d-CDCl3) δ 158.3, 151.5, 151.4, 151.3, 151.2, 145.1, 143.1   
142.9, 142.0, 141.8, 136.3, 130.0, 130.0, 129.9, 129.9, 129.7, 129.7, 129.3   129.2, 129.1, 
128.1, 127.8, 127.8, 127.7, 127.7, 126.6, 123.0, 122.9, 122.7, 120.9, 120.5, 113.1  113.0, 
113.0, 86.0, 77.4, 77.1, 76.7, 67.9,  64.4,   63.4, 63.3, 55.25, 55.20 53.4; ESI-HRMS (ES+) 










 To a solution of 4.00 mL of anhydrous DCM/ACN (1:1) 0.26 g of compound 2 
(0.45 mmol, 1.00 equiv.) was added to a flame dried flask. To that solution 0.63 mL of 
anhydrous triethylamine (4.50 mmol, 10.0 equiv.) was added along with 0.30 mL of       2-
cyanoethyl N,N-diisopropylchlorophosphoramidite with (1.35 mmol, 3.00 equiv.) and 
stirred at room temperature until TLC showed starting materials were consumed (3 h). 
After rotary evaporation, the compound was then purified on silica gel using a 
68%:30%:2% hexanes/ethyl acetate/triethylamine mobile phase.  This afforded compound 
3 as an orange oil (0.22 g, 63%). 1H NMR (400 MHz, d-CDCl3) δ 7.82 - 7.88 (m, 4H) 7.32 
- 7.41 (m, 6H) 7.27 - 7.30 (m, 4H) 7.21 - 7.25 (m, 3H) 6.84 (d, J = 8.99 Hz, 4H) 6.76 - 6.81 
(m, 3H) 4.13 (q, J = 7.29 Hz, 2H) 3.84-3.94 (m, J = 7.42 Hz, 1H) 3.75 - 3.81 (m, 6 H) 3.55 
- 3.67 (m, 1H) 3.35 (t, J = 6.64 Hz, 2H) 2.93 - 2.98 (t, J = 6.74 Hz, 2H) 1.50 (d, J = 6.64 
Hz, 1H) 1.27 (t, J = 7.23 Hz, 6H) 1.17 (dd, J = 10.75, 6H).13C NMR (101 MHz, d-CDCl3) 
δ 158.6, 158.3, 151.2, 145.1, 142.9, 136.3, 130.0, 129.9, 129.9, 129.7, 129.1, 128.1, 127.8, 
127.7, 127.7, 127.0, 126.6, 122.7, 122.7, 122.6, 113.1 113.0 112.9, 86.0, 77.3, 77.0, 76.7, 
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64.3, 60.3, 55.2, 55.1, 43.1, 43.0, 36.6, 24.6, 24.5, 24.5, 21.0, 14.2. 31P NMR (162 MHz, 
d-CDCl3) δ ppm 147.54, 147.13 ESI-HRMS (ES
+) m/z calculated for C46H53N4O5P: 
772.4797, found 703.3949 [M+H]+ (Hydrolyzed product). 




  To a solution of 90.0 mL of 5.70 M NaOH(aq) 4.00 g of 4-nitrobenzyl alcohol (26.1 
mmol, 1.00 equiv.) was added and stirred until fully dissolved. To this solution 6.00 g of 
Zn powder (92.3 mmol, 3.53 equiv.) was slowly added to maintain stirring. After refluxing 
overnight for 16 h it was then filtered on a Buchner Vacuum filter, and the crystals were 
suspended in hot methanol.  The crystals were collected and filtered again with a gravity 
filter to remove residual salts and then the methanol solution was removed using a rotary 
evaporator. Crystals were collected and purified on silica gel column using MeOH (2% to 
5%) in CH2Cl2 to afford compound 4 as orange crystals (2.13 g, 67%). 
1H NMR (400 MHz, 
d6-DMSO) δ 7.85 (d, J = 8.60 Hz, 4H) 7.51 (d, J = 8.21 Hz, 4H) 5.35 (s,2 H) 4.59 (d, J = 
5.47 Hz, 4H). 13C NMR (101 MHz, d6-DMSO)  δ 146.2, 127.0, 122.3, 105.8,  63.4. ESI-








2.2.5 Synthesis of 4-hydroxymethyl-4’-O-(4,4’dimethoxytrityl)-azobenzene (5) 
 
(5) 
 To a solution of 30.0 mL of anhydrous THF 1.5 g of compound 4 (6.19 mmol, 1.00 
equiv.) was added and stirred until fully dissolved. To the solution 2.09 g of 4,4’-
dimethoxytrityl chloride (6.19 mmol, 1.00 equiv.) was added along with 2.60 mL of 
triethylamine (18.6 mmol, 3.00 equiv.) The reaction mixture was stirred vigorously 
overnight and monitored by TLC. The crude reaction was then concentrated by rotovap 
and purified on silica gel column using MeOH (2% to 5%) in CH2Cl2 to afford compound 
5 as an orange oil (1.11 g, 33%). 1H NMR (400 MHz, d-CDCl3): δ 7.87 (m, 4H) 7.51 (m, 
6H) 7.44 (m, 4 H) 7.32 (t, J = 7.62 Hz, 3H) 6.82 (m, 4H) 4.59 (s, 2H) 4.18 (s, 2H) 3.8 (s, 
6H).13C NMR (101 MHz, d-CDCl3)  δ 158.6, 158.2, 151.3, 146.6, 145.2, 140.6, 135.9, 
130.1, 129.3, 128.4, 128.0, 127.9, 127.8, 127.5, 123.0, 122.8, 113.7, 113.2, 86.5, 62.9, 55.5, 







2.2.6 Synthesis of 2-Cyanoethyl-4-O-{[4-hydroxymethyl-4’-O-(4,4’dimethoxytrityl)-
O-methyl-diazenyl]}-N,N’-diisopropylaminophosphoramidite  (6) 
 
(6) 
To a solution of 4.00 mL of anhydrous DCM/ACN (1:1) 247 mg of compound 5 (0.45 
mmol, 1.00 equiv.) was added to a flame dried flask. To that solution 0.63 mL of anhydrous 
triethylamine (4.50 mmol, 10.0 equiv.) was added along with 0.30 mL of        2-cyanoethyl 
N,N-diisopropylchlorophosphoramidite with (1.35 mmol, 3.00 equiv.) and stirred at room 
temperature until TLC showed starting materials were consumed (3 h). After rotary 
evaporation, the compound was then purified on silica gel using a 68%:30%:2% 
hexanes/ethyl acetate/triethylamine mobile phase.  This afforded compound 6 as an orange 
oil (0.23 g, 66%). 1H NMR (400 MHz, d-CDCl3)  δ 7.88 - 7.94 (m, 4H) 7.50 - 7.56 (m, 5H) 
7.39 - 7.45 (m, 3H) 7.29 - 7.33 (m, 1H) 6.83 - 6.89 (m, 4 H) 4.80 (dd, J = 19.73, 8.40 Hz, 
1 H) 4.26 (s, 2 H) 4.09 - 4.16 (m, 1H) 3.82 - 3.93 (m, 2H) 3.79 - 3.81 (m, 6H) 3.59 - 3.73 
(m, 2H) 2.62 - 2.68 (m, 2H) 1.18 - 1.25 (m, 12H). 13C NMR (101 MHz, d-CDCl3)  ppm 
158.3, 152.0, 150.7, 144.8, 141.9, 141.5, 136.1, 130.0, 129.7, 128.2, 127.7, 127.5, 127.4, 
126.6, 122.8, 122.7, 122.6, 117.6, 113.1, 113.0, 86.4, 77.3, 77.0, 76.7, 65.2, 65.0, 58.5, 
58.3, 58.3, 55.1, 51.8, 50.7, 50.5,  46.3, 43.2, 43.1, 43.0, 42.8, 24.7, 24.6, 24.6, 24.6, 24.5, 
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22.8, 21.5, 20.4, 20.3, 20.3. 31P NMR (162 MHz, d-CDCl3) δ ppm 149.37, 148.72. 
C46H53N4O5P: 744.87, found 660.34 [M+H]
+ (Hydrolyzed product). 
 
2.3 Procedure for Oligonucleotide Synthesis and Purification 
All standard β-cyanoethyl 2'-O-TBDMS protected phosphoramidites, reagents and 
solid supports were purchased from Chemgenes Corporation and Glen Research. Wild-
type luciferase strands including the sense and 5'-phosphorylated antisense strand were 
synthesized. All commercial phosphoramidites were dissolved in anhydrous acetonitrile to 
a concentration of 0.10 M. The chemically synthesized (azobenzene derivative) 
phosphoramidites were dissolved in 3:1 (v/v) acetonitrile:THF (anhydrous) to a 
concentration of 0.10 M. The reagents that were used for the phosphoramidite coupling 
cycle were: acetic anhydride/pyridine/THF (Cap A), 16% N-methylimidazole in THF (Cap 
B), 0.25 M 5-ethylthio tetrazole in ACN (activator), 0.02 M iodine/pyridine/H2O/THF 
(oxidation solution), and 3% trichloroacetic acid/dichloromethane. All sequences were 
synthesized on 0.20 μM or 1.00 μM dT solid supports except for sequences that were 3'-
modified, which were synthesized on 1.00 μM Universal III solid supports. The entire 
synthesis ran on an Applied Biosystems 394 DNA/RNA synthesizer using 0.20 μM or 1.00 
μM cycles kept under argon at 55 psi. Standard and synthetic phosphoramidites ran with 
coupling times of 999 seconds. 
Antisense sequences were chemically phosphorylated at the 5'-end by using 2-[2-
(4,4’-dimethoxytrityloxy)ethylsulfonyl]ethyl-(2-cyanoethyl)-(N,N-diisopropyl)-
phosphoramidite. At the end of every cycle, the columns were removed from the 
synthesizer, dried with a stream of argon gas, sealed and stored at 4 °C. Cleavage of 
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oligonucleotides from their solid supports was performed through on-column exposure to 
1.50 mL of EMAM (methylamine 40% wt. in H2O and methylamine 33% wt. in ethanol, 
1:1 (Sigma-Aldrich)) for 1 hour at room temperature with the solution in full contact with 
the controlled pore glass. The oligonucleotides were then incubated overnight at room 
temperature in EMAM to deprotect the bases. On the following day, the samples were 
concentrated on a Speedvac evaporator overnight, resuspended in a solution of 
DMSO:3HF/TEA (100 μL:125 μL) and incubated at 65 °C for 3 hours in order to remove 
the 2'-O-TDBMS protecting groups. Crude oligonucleotides were precipitated in EtOH and 
desalted through Millipore Amicon Ultra 3000 MW cellulose. Oligonucleotides were 
separated on a 20% acrylamide gel and were used without further purification for annealing 
and transfection. Equimolar amounts of complimentary RNAs were annealed at 95 °C for 
2 min in a binding buffer (75.0 mM KCl, 50.0 mM Tris-HCl, 3.00 mM MgCl2, pH 8.30) 
and this solution was cooled slowly to room temperature to generate siRNAs used for 
biological assays. A sodium phosphate buffer (90.0 mM NaCl, 10.0 mM Na2HPO4, 1.00 
mM EDTA, pH 7.00) was used to anneal strands for biophysical measurements. 
2.4 Biophysical Characterization 
2.4.1 Procedure for Performing CD Experiments 
Circular Dichroism (CD) spectroscopy was performed on a Jasco J-815 CD 
equipped with temperature controller. Equimolar amounts of each siRNA (10 μM) were 
annealed to their compliment in 500 μL of a sodium phosphate buffer. CD measurement of 
each duplex were recorded in triplicate from 200-500 nm at 25 °C with a screening rate of 
20.0 nm/min and a 0.20 nm data pitch. The average of the three replicates was calculated 
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using Jasco’s Spectra Manager version 2 software and adjusted against the baseline 
measurement of the sodium phosphate buffer.  
 
2.4.2 Procedure for Absorbance Spectra Experiments 
All absorbance spectra measurements were done on a Jasco J-815 CD with 
temperature controller. Measurement was recorded from 200 -500 nm at 10 °C at least 3 
times. UV treated samples were placed under a UVP UVL-23RW Compact UV lamp 4.00 
W 365 nm for the indicated time at 25 °C . Visible light treated samples were placed under 
a 60.0 W daylight bulb from NOMA in standard desk lamp.  
 
2.4.3 Procedure for HPLC Characterization 
 HPLC chromatograms were obtained on a Waters 1525 binary HPLC pump with a 
Waters 2489 UV/Vis detector using the Empower 3 software. A C18 4.6 mm x 150 mm 
reverse phase column was used. Conditions were 5% acetonitrile in 95% 0.1 M TEAA 
(Triethylamine-Acetic Acid) buffer up to 100% acetonitrile over 40 min. 
2.5 Maintaining Cell Cultures 
 
 For biological analysis of these siRNAs in a live environment, human epithelial 
cervix carcinoma cells were   used (HeLa cells). They were kept in 250 mL vented culture 
flasks using 25.0 mL of DMEM with 10% fetal bovine serum and 1% penicillin-




 Once cell lines became confluent (80-90%) they were passaged by washing 3 times 
with 10 mL of phosphate buffered saline (NaCl 137 mM, KCl 2.70 mM, PO4
3-
 10.0 mM, 
pH 7.40) and incubated with 3.00 mL of 0.25% trypsin (SAFC bioscience) for 4 min @ 37 
°C to detach the cells. The cells were transferred to a 50.0 mL centrifuge tube after the 
addition of 10.0 mL of DMEM solution and pelleted at 2000 rpm for 5 minutes.  The 
supernatant was discarded and the pellet resuspended in 5.0 mL DMEM with 10% FBS. 
A standard haemocytometer was used to obtain cell counts, after which the cells 
were diluted to a final concentration of 1.00 x 106 cells/mL for subsequent assays. To 
continue the cell line 1.00 mL of freshly passaged cells was added to 24.0 mL of 
DMEM/10% FBS and 1% penicillin-streptomycin at 37 °C in a new culture flask while the 
rest were used for assays. 
 
2.6 Cell Based Assays 
2.6.1 Procedure for siRNA Transfections 
100 μL of cells (total 1.00 x 105) were transferred into 12 well plates (Falcon®) 
with 1 mL of DMEM (10% FBS, 1% penicillin-streptomycin) and incubated at 37 °C with 
5% CO2. After 24 hours the cells were transfected with various concentrations of siRNAs, 
along with both pGL3 (Promega) and pRLSV40 luciferase plasmids using Lipofectamine 
2000 (Invitrogen) in Gibco’s 1X Opti-Mem reduced serum media (Invitrogen) according 
to the manufacturer’s instructions. 1.00 μL of siRNA was added along with 2.00 μL (pGL3 
200 ng) and 0.50 μL pRLSV40 (50.0 ng) to 100 μL of 1X Opti-Mem in a microcentrifuge 
tube and kept on ice for 5 min. In a different microcentrifuge tube 1.00 μL of Lipofectamine 
2000 (Invitrogen) was mixed with 100 μL of Gibco’s 1X Opti-Mem reduced serum media 
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(Invitrogen) and incubated at room temperature for 5 min. After 5 minutes the tubes were 
mixed and incubated at room temperature for 20 min and then the entire contents 
transferred to the wells of the 12 well plate. 
2.6.2 Procedure for in vitro Dual-Reporter Luciferase Assay 
100 μL of cells (total of 1.00 x 105 cells) were added to 12 well plates (Falcon®) 
with 1 mL of growth media (DMEM 10% FBS, 1% penicillin-streptomycin) and incubated 
at 37 °C with 5% CO2. After 24 hours the cells were transfected with 8.00, 20.0, 40.0, 160, 
400 and 800 pM concentrations of siRNAs, co-transfected with both the pGL3 (Promega) 
coding for the firefly luciferase protein and the pRLSV40  Renilla luciferase plasmids using 
Lipofectamine 2000 (Invitrogen) in Gibco’s 1X Opti-Mem reduced serum media 
(Invitrogen) according to the manufacturer’s instructions. After a set amount of time (8, 12 
or 22 h) the cells were incubated at room temperature in 1X passive lysis buffer (Promega) 
for 20 minutes. The lysates were collected and loaded onto a 96 well, opaque plate (Costar). 
With a Dual-Luciferase reporter Assay kit (Promega), Lar II enzyme solution was added 
which produces the photochemical reaction with the firefly luciferin protein.  Stop & Glo® 
with the Renilla luciferase enzyme was sequentially added to the same lysate and enzyme 
activity was measured through luminescence of both firefly and Renilla luciferin on a 
Synergy HT (Bio-Tek) plate luminometer. The ratio of firefly and Renilla luminescence is 
expressed as a percentage to untreated controls for siRNA efficacy. Each value is the 





2.6.3 Procedure for Light Inactivation of Azobenzene Modified siRNA (trans to cis) 
1.00 μL of the desired siRNA was added to a microcentrifuge tube and exposed to 
a 4.00 W 365 nm UV lamp (UVP) at 25 °C and was exposed for at least 4 hours. Longer 
exposure times required the addition of a small amount of RNAse free water to prevent 
evaporation. 
After UV exposure the siRNA can be used in the transfection procedure above, but 
the transfection must be done in the dark room, at 25 °C to prevent the cis to trans 
conversion back into the active form. 
2.6.4 Procedure for Light Reactivation of Azobenzene Modified siRNA (cis to trans) 
 4 hours after the transfection procedure, the plate was exposed to a 60.0 W daylight 
bulb (NOMA) and left under the visible lamp for  4 h (8 h assay) or 8 h (12 h assay) after 











3.0 Results and Discussion 
3.1 Organic synthesis of Phosphoramidites 
 In this study a small library of azobenzene modified siRNAs were synthesized in 
order to increase the scope of possible modifications of the central region of siRNAs. This 
was done using azobenzene spacer phosphoramidites which were then incorporated into 
oligonucleotides using solid phase synthesis. Two azobenzene derivatives were 
synthesized for use as DMT-phosphoramidite spacers as shown in Figure 3.1: 
 
Figure 3.1. Azobenzene Derivatives  
 In order to obtain the nitrogen double bond functionality of the azobenzene, the 
synthesis begins with either 4-nitropenethyl alcohol (Az2) or 4-nitrobenzyl alcohol (Az1). 
The nitro-alcohols were added to a concentrated basic solution of 5.7 M NaOH in order to 
reduce the nitro group through a nitrosobenzene (R-N=O) intermediate and becoming an 
aniline (R-NH2) functional group when fully reduced. For this to occur an electron source 
is required and Zn powder was used to accomplish this.   
One possible pathway for this reduction where the nitro group becomes protonated 
and then an electron is able to attack the positive nitrogen. Subsequent to this attack the  
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hydroxyl group is protonated after the N=O bond reforms and leaves as water forming a 
nitrosobenzene group. The lone electron on the nitrogen is then protonated and 
consequently a new electron from a Zn atom can attack the nitrogen. Since this is done 
under basic conditions, the formation of a hydroxyl ion is favourable and addition of an 
electron can allow it to form and leave a negatively charged nitrogen behind. Protonation 
of the nitrogen gives the 4-aminobenzyl alcohol which is required for the next step. 
 
Figure 3.2. Final Steps of Azobenzene Formation 
 In Figure 3.2, the azobenzene functional group finally begins to take shape. This 
begins with an attack by the lone pair of electrons on the –NH2 group of the 4-aminobenzyl 
alcohol on the 4-nitrosobenzyl alcohol’s –N=O group. This forms a σ bond between each 
nitrogen. This allows the negatively charged oxygen to be protonated, after which a proton 
can be removed from the positive nitrogen as well. Once this occurs, a condensation 
reaction where a water molecule is removed and allows the π bond to form between the 
nitrogens. This has the added effect of making the molecule planar, indicative of trans 
azobenzene. These steps resulted in the formation of compound 1 and compound 2 in a 
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70% yield. This kind of chemistry results in a symmetrical molecule, whereas the often 
used diazonium groups may not have given the symmetry required. These diazonium 
coupling reactions usually occur at the para position, but by-products could be formed as 
well depending on the substituents present on the benzene ring.83 
As shown in Scheme 3.1, both compounds were then protected with dimethoxytrityl 
chloride. This is group is often used for the protection of primary alcohols in 
oligonucleotide synthesis because it is easy to remove with weak acidic conditions, and the 
formation of the carbocation results in a bright orange colour that make coupling easy to 
monitor.83 Attaching a DMT group to a di-alcohol (diol) such as this can prove to be 
problematic, since it possible to get double protection of both alcohols, rendering it useless 
for the next step. This is reflected in the yields, which proved to be low for both compounds 
3 and 4 at 35%. To try and mitigate this, one equivalent (or less) of DMT-Cl is used to try 
and prevent double protection. The final step is the attachment of a phosphite group. This 
can be synthetically challenging because the phosphite is sensitive to both heat and 
moisture, and the ambient amount of water present in the atmosphere can be enough to 
degrade it.84 The phosphite was attached to the other end of the spacer using a weak amine 
base, triethylamine, at room temperature under an Argon atmosphere. This produced 
compounds 5 and 6 in yields of 63% and 33% respectively. During oligonucleotide 




Scheme 3.1. Synthesis of Azobenzene DMT-phosphoramidite Spacers 
 
 
3.2 Photoswitching Ability of Azobenzene Derivatives, Lability and siRNAs 
 In order to confirm the azobenzene’s ability to change conformation the first 
experiments that were run were absorbance spectra. As seen in Figure 3.4, exposure to UV 
light causes a decrease in the maximum absorbance around 330 nm, and exposure to visible 
light causes the absorbance to increase. This agrees with  the literature showing that as the 
trans isomer of azobenzene absorbs UV light, and converts to the cis isomer, absorbance 
decreases. The opposite effect also occurs upon exposure to visible light with the cis form 












After photoswitching ability was confirmed, we then proceeded to synthesize the siRNAs 
shown in Table 3.1 with Az1 and Az2 in various locations. After synthesis, we ran a new 
absorbance spectra experiment with the expectation that there would be large maxima in 2 
locations: at 260 nm since that is where nucleobases absorb most strongly, and at 330 nm, 
where the azobenzene derivatives absorb. This is exactly what was found, and Figure 3.4 
shows how the maxima change when exposed to UV (decreases) and visible (increases) 
light. This is reflected in the literature as well69-74 and all siRNAs shared a similar profile 
and ability to return to the trans conformer (See Appendix 1). A lability test was performed 
to make sure the N=N double bond was robust and would not fail after multiple conversions 
from trans to cis to trans.  
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Figure 3.4. Absorbance Profile of siRNA 7 when exposed to UV and Visible light.  
Inset: Zoomed in portion of 300-380 nm highlighting Az1 changes 
 
Using siRNA 7, the same sample was exposed to multiple iterations of alternating visible 
and UV light and the relative absorbance was measured and is shown in Figure 3.5. 
 






































Each time point is 5 min of alternating visible  UV  exposure, and highlights the robust 
nature of the conformational change. As can clearly be seen, there is no loss in the ability 
of the azobenzene to interconvert even after several exposures.54,56 All of our siRNA 
constructs had similar results (Appendix 1). In a paper from 1995, Ikeda et al. attempted to 
exploit this lability to try and make more efficient liquid crystal films. They found not only 
does the isomerization occur on the order of 10 ns, but that several laser pulses show no 
loss of the ability to transform.90  
Figure 3.6. HPLC chromatogram of siRNA 10 with cis and trans peaks indicated 
To further characterize the trans and cis functionality, siRNA 10 was purified using 
HPLC (High Pressure Liquid Chromotography). The chromatogram in Figure 3.7 clearly 
shows two peaks, one at 16.8 min and one at 17.7. The trans peak is much larger, which 
would be expected since at room temperature, the trans is the dominant form.59,92 
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Interestingly, exposure to UV light causes the peaks to shift not in retention time, but in 
abundance and  the cis peak grows and the trans peaks recedes ( Figure 3.8). 
Figure 3.7. HPLC chromatogram of siRNA 10 measured immediately after 60 min UV 
exposure with cis and trans peaks indicated 
 These results indicate that there are in fact two different conformers coexisting at 
room temperature, and exposure to UV light causes the interconversion from trans to cis 
but also confirms the cis conformer has a lower retention time than trans and agrees well 
with the body of literature.92 Appendix 1 has the chromatograms for all central region 
siRNAs avavilable, and show similar results. 
3.3 Thermal Stability of siRNAs 
 The siRNA helix is stable because of two main types of interactions; hydrogen 
bonding and base stacking.85 The melting temperature (Tm), is the temperature that there is 
an equal amount of double stranded and single stranded RNA present, since as the 
temperature increases, the two strands become unstable and dissociate. This is a useful 
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property when looking to measure how stable a RNA duplex is. More stable duplexes will 
have higher Tm temperatures. Nucleobases have a maximum absorption at 260 nm, and this 
makes it easy to measure the Tm since exposed nucleobases will have an increased 
absorbance, much higher than their double stranded counterparts.87 Comparing thermal 
stabilities to wild type siRNA can determine whether these azobenzene modified strands 
are more or less stable and how that can affect activity of the siRNA. Table 3.1 displays 
the sequences, modifications, Tm’s and the mass spectrometry results of the siRNA sense 
strands. 
Table 3.1. Sequences of anti-luciferase siRNAs, mass spec and Tm’s of siRNAs 
containing the azobenzene spacers. 
     siRNA                         siRNA Duplex Predicted 
Mass 






wt       5’- C UUA CGC UGA GUA CUU CGAtt -3’ (s) 
    3’- ttG AAU GCG ACU CAU GAA GCU – 5’(as) 
 
      
 
73.99 -- 
7 5’- C UUA CGC UAz1 GUA CUU CGAtt -3’ (s) 






52.68 - 21.31 
8 5’- C UUA CGC UGA GUA CUU CGA Az1 -3’ (s) 










9 5’- C UUA CGC Az2 A GUA CUU CGAtt -3’ (s) 










10 5’- C UUA CGC U Az2  GUA CUU CGAtt -3’ (s) 










11 5’- C UUA CGC UG Az2 UA CUU CGAtt -3’ (s) 










12 5’- C UUA CGC UGA Az2 A CUU CGAtt -3’ (s) 










13 5’- C UUA CGC UGA GUA CUU CGA Az2 -3’ (s) 










 The azobenzene modification locations are Az1 
for the 1 carbon species and Az2 for the 2 carbon 
species 




It should come as no surprise that replacing two natural nucleobases with an 
unnatural molecule would cause disruption in both the base stacking and hydrogen bonding 
of the duplex.88 This destabilization is reflected in the Tm measurements above, where every 
case of a central modification resulted in a decrease of Tm compared to wild-type siRNA. 
Interesting to note is that Az1 (siRNA 7) is twice as destabilizing as Az2  
(siRNA 10) when replacing the Ago2 cleavage site at base pairs 9 and 10. Also interesting 
is that moving the Az2 spacer towards the 3’-end causes it to be more destabilizing than 
when replacing the cleavage site (siRNA 11 and 12).  In the study done  
by Desaulniers et al. (2017) their biphenyl modification had similar destabilization, 15 °C 
less than wildtype.77 Depending on the position, the chemical modifications to the siRNA 
can be more or less stabilizing than the biphenyl linker perhaps due to their supra position 
in the major or minor groove. The major groove would likely be more accommodating than 
the minor, and this could explain some of the difference.89 In all cases the same number of 
hydrogen bonds are being replaced, one A-U and and C-G base pair, so that cannot be the 
source of the variable destabilization. When exposed to UV light, there was found to be no 
difference in Tm which was unexpected. If the proposed change from trans to cis prevents 
activity in vivo then one would expect a resulting change in the Tm. This was not observed 
however  
despite the literature showing it occurring in several other types of nucleic acids.67,69 Figure 
3.8 shows a proposed structural change when going from trans to cis.  
As seen in Figure 3.8, a large amount hydrogen bonding is still occurring, and this 
could help to explain why the melting temperatures remain stable even after exposure to 
UV light. One more interesting thing was that both Az1 and Az2 (siRNAs 8 and 13 
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respectively) when placed at the 3’-end actually caused an increase in Tm of 8.22 - 8.73 °C. 
This could simply be due to the azobenzene derivatives having a favourable interaction  
 
Figure 3.8. Proposed Structural Change 
 
with the anti sense strand as compared to the double thymine endcaps on each of the other 
sense strands. A study by Perez-Rentero et al. 2013 indicates that pyrenes and other π-
conjugated compounds did increase the Tm by 2-5 °C.
104 Another study by Brotschi et al. 
in 2005  found that increasing biphenyl substituted deoxynucleotides centrally could 
increase Tm by up to 10 °C .105 These 3’-end azobenzenes also have a free hydroxyl group 
that may be able to hydrogen bond, as well being free to intercalate in between the bases 






3.4 Circular Dichroism Conformation of siRNA Helical Structure 
In order to determine whether the siRNAs maintained their A-form helical 
conformation, CD (Circular Dichroism) spectra were measured. If the A-form helix is not 
present, it is not able to be a tolerable substrate for RISC.93 Interactions between 
asymmetrical molecules and circularly plane polarized light causes distinct absorption 
patterns to emerge based on the secondary structure of nucleic acids and proteins.94  
 
Figure 3.9. CD spectra of azobenzene modified spacers replacing two nucleobases 
targeting firefly luciferase mRNAs. Wildtype and modified anti-firefly luciferase siRNAs 
(10 μM/duplex) were suspended in 500 μL of a sodium phosphate buffer (90.0 mM NaCl, 
10.0 mM Na2HPO4, 1.00 mM EDTA, pH 7.00) and scanned from 200-300 nm at 25 °C 
with a screening rate of 20.0 nm/min and a 0.20 nm data pitch. All scans were performed 
in triplicate and averaged using Jasco’s Spectra Manager version 2.  
 
Figure 3.9 shows the CD spectra of the azobenzene modified duplexes 
demonstrating a typical absorption pattern for an A- form helix. Each kind of helix (A, B 































troughs at around 210 nm and a large absorption maxima at 260 nm. B-form helices are 
similar but have a 10 and 20 nm shift to the right (to 220 nm and 280 nm respectively). B- 
form helices are most often exhibited by DNA duplexes.96 The Z-form has a distinct sharp 
trough at 205 nm, a large peak at 260 nm and smaller trough around 290 nm, but is less 
common than the other two forms.97 While there appears to be some small deviations in 
the helices compared to the wildtype, these siRNAs are all confirmed as A-form helices 
and should therefore be an active substrate for RISC.93  
 
3.5 Silencing Capability of Azobenzene Modified siRNAs of the Exogenous Firefly 
Luciferase Gene 
 
 After the battery of biophysical tests performed, it was determined that the modified 
siRNAs would not only be compatible with RNAi, but that temporal and spacial control of 
the siRNAs should be possible with light. To determine this the dual luciferase assay was 
used. The dual luciferase assay is widely used as a way to test potential gene knockdown 
of siRNAs on an easily detected exogenous target. These siRNAs target the firefly 
luciferase mRNA (expressed with the pGL3 plasmid) while Renilla luciferase (SV40 
plasmid) is used as an internal control to normalize the signal. When luciferase enzymes 
from the assay kit are added to the substrate luciferin, they catalyze a light producing 
reaction98 which is measured as luminescence.99,100 A control well was utilized on each 
plate by co-transfecting a well with both plasmids only with no siRNA present. The control 
was then used to express luciferase luminescence as a percent of the control. As shown in 





Figure 3.10. Gene silencing capability of azobenzene spacer modified siRNAs 7-13 and 
wildtype targeting firefly luciferase mRNA at 8, 20, 40, 80, 160, 400 and 800 pM 
concentrations and normalized to Renilla luciferase in HeLa cells and lysed 22 h post 
transfection. Untreated control was co-transfected with both plasmids with no siRNA 
present. 
  
Each siRNA operates in a dose dependent manner, and in some cases, the 3’-end 
modified siRNAs 8 and 13, is comparable to wild type. Despite high efficiency at large 
doses (800 pM) decreasing the concentration of the siRNAs causes a fold decrease in 
activity  compared to wild type. This shows that even with high destabilization of the 
duplex, these azobenzene modified siRNAs are well tolerated  
 
within RISC as a substrate. This agrees with Addepalli et al.’s 2010 study in which they 
presented findings that position based destabilization of the duplex can increase potency of 
the RNAi substrate.101  
Further investigation into the dose dependency produced the IC50 (Inhibitory 



































































Looking at Table 3.2, siRNAs 8 and 13 have the lowest IC50 values only slightly 
above wild type. This would be expected since no destabilization occurred in these two 
oligonucleotides. Interestingly, the next lowest values were for siRNAs 11 and 12 at 28.4 
and 45.76 pM respectively. Both of these modifications were closer to the 5’-end of the 
antisense strand, and that makes it likely the dose was lower since it was easier to unwind 
the duplex100 and allowed RISC to select the guide strand because of the destabilizing 
nature of Az2. The remaining oligonucleotide strands were from 99-235 pM either because 
it was too destabilizing, or it was interfering with the selection of the guide strand 
somehow. 
3.6 Inactivation of the Silencing Capability of Azobenzene Modified siRNAs of the 
Exogenous Firefly Luciferase Gene with UV Light 
 
 Having established good dose dependency of the siRNAs and its ability to function 
supported, the next experiment was designed to inactive the siRNAs with UV light. This 
proved to be challenging, since exposure to UV light is detrimental to cell cultures. UV 
light is damaging to DNA and to other cellular functions, especially in cell cultures.102 To 
bypass the difficulty of exposing cell culture to UV light, the siRNAs were pre-inactivated 
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prior to transfection with the UV lamp. The subsequent transfection was then carried out 
in the dark, to prevent reactivation by visible light. A second difficulty also had to be 
overcome and that was the rate of thermal relaxation at 37 °C.60 Since the cis form is not  
thermally stable at physiological temperatures, these inactivation assays had to be 
performed at 8 h time points instead of the normal 24 h time points. Time points past 8 h 
showed reduced effectiveness of the inactivation of the siRNA as the azobenzene slowly 
reactivated itself through thermal conversion of cis to trans isoforms. Despite these two 
major hurdles, pre-inactivation was found to be effective, Figure 3.12 supports inactivation 
of the siRNA was successful, in some cases to near control levels. The data for siRNAs 7, 
11 and 12  with concentrations of 800, 400 and 80.0 pM were selected to showcase this 
effect because the other siRNAs were ineffective at this time point, and lower 
concentrations below 80 pM showed no difference between UV exposure and  untreated 
samples. 
Figure 3.11. Gene silencing capability of azobenzene spacer modified siRNA targeting 
firefly luciferase mRNA and normalized to Renilla luciferase for siRNAs 7, 11 and 12 at a 
80, 400 and 800 pM concentrations in HeLa cells and lysed 16 h post transfection. UV 
corresponds to the siRNA being exposed under a 365nm UV lamp for inactivation prior to 

































































of both UV and visible light. Untreated control was co-transfected with both plasmids with 
no siRNA present. 
 
 
Showcasing Figure 3.11, the trend is easy to see, exposure to UV light causes the 
siRNA to become ineffective. This is shown across 3 different siRNAs (7, 11, 12) and 3 
concentrations (80, 400 and 800 pM). The dose dependency is harder to see with UV 
inactivated wells, but generally lower doses resulted in higher luciferase levels after UV 
treatment. Interesting to note is that siRNA 7 with the Az1 spacer was able to get near 
control levels after inactivation even at 800 pM. This may be due to the fact that spacer 
itself is 2 carbons shorter, and so has less flexibility when in the cis conformer resulting in 
an impressive inactivation.103 These results support the inactivation of the siRNAs after 
UV light exposure, and the next step is reactivation with visible light 
3.6 Reactivation of the Silencing Capability of Azobenzene Modified siRNAs of the 
Exogenous Firefly Luciferase Gene with UV Light 
 
In order to test the reactivation of the siRNAs, the experiment was set up as 
previous, but with one major change: one plate was  exposed to visible light in the incubator 






Figure 3.12. Reduction in normalized firefly luciferase expression for siRNA 7 at 
160 and 800 pM in HeLa cells monitored 8 and 12 hours post-transfection. 1) UV 
corresponds to the siRNA being exposed under a 365nm UV lamp for inactivation prior to 
transfection. 2) Vis corresponds to the siRNA being exposed under a 365nm UV lamp for 
inactivation prior to transfection, however the transfected cells were exposed to a 13 W 
daylight lamp 4 hours post-transfection for the remainder of the assay. 3) No light 
corresponds to siRNAs being transfected in HeLa cells in the absence of both UV and 




In figure 3.12,  which shows the data for siRNA 7, the only Az1 internal spacer 
were able to synthesize, UV corresponds to the previous treatment for inactivation, and Vis 
is the visible light treated plate 4 h post transfection while no light is the untreated plate 
with baseline levels of activity. The concentrations shown were selected in order to 
demonstrate that high doses (800 pM) of siRNA does not cause significant cell death, and 
a lower concentration is able to be inactivated and reactivated successfully. The time points 
were chosen because 8 h was the earliest time point that showed significant accumulation 
of the luciferin proteins, and the 12 h ( 1 half life) time point was selected to show the effect 



















































time points exhibit clear trends where UV inactivation has higher levels of luciferin than 
both the reactivated visible treated cells and the untreated no light cells. In both cases the 
Vis treated cells have levels in between UV and no light, but in the case of the 12 h time 
point all activity levels are much lower than the 8 h time point, and this is due to the thermal 
relaxation mentioned previously. With a half life of 4 h the 12 h time point could have as 
much as twice as much active siRNA resulting in the lower expression levels.60 In contrast 
the 160 pM concentration exhibits its own trends. While UV inactivation was higher than 
both visible and untreated cells, the visible and no light treatments gave comparable levels 
of activity. This could have been due to having less siRNA present to be deactivated, or 
that it was being degraded at a similar rate for both treatments. 
 
Figure 3.13. Reduction in normalized firefly luciferase expression for siRNA 9 at 
160 and 800 pM in HeLa cells monitored 8 and 12 hours post-transfection. 1) UV 
corresponds to the siRNA being exposed under a 365nm UV lamp for inactivation prior to 
transfection. 2) Vis corresponds to the siRNA being exposed under a 365nm UV lamp for 
inactivation prior to transfection, however the transfected cells were exposed to a 13 W 
daylight lamp 4 hours post-transfection for the remainder of the assay. 3) No light 
corresponds to siRNAs being transfected in HeLa cells in the absence of both UV and 



















































Results for siRNA 9 shown in Figure 3.13, follow the same trends discussed 
previously, but with better results at the 160 pM, 8 h time point. This could be due to the  
the Az2 spacer, or that the location of the spacer was more favourable than in siRNA 7. 
Showing the same trend in a second siRNA,  a clear inactivation effect under UV light, is 
observed and a clear reactivation when exposed to visible light. 
 
Figure 3.14. Reduction in normalized firefly luciferase expression for siRNA 10 at 
160 and 800 pM in HeLa cells monitored 8 and 12 hours post-transfection. 1) UV 
corresponds to the siRNA being exposed under a 365nm UV lamp for inactivation prior to 
transfection. 2) Vis corresponds to the siRNA being exposed under a 365nm UV lamp for 
inactivation prior to transfection, however the transfected cells were exposed to a 13 W 
daylight lamp 4 hours post-transfection for the remainder of the assay. 3) No light 
corresponds to siRNAs being transfected in HeLa cells in the absence of both UV and 

























































Figure 3.15..Reduction in normalized firefly luciferase expression for siRNA 11 at 
160 and 800 pM in HeLa cells monitored 8 and 12 hours post-transfection. 1) UV 
corresponds to the siRNA being exposed under a 365nm UV lamp for inactivation prior to 
transfection. 2) Vis corresponds to the siRNA being exposed under a 365nm UV lamp for 
inactivation prior to transfection, however the transfected cells were exposed to a 13 W 
daylight lamp 4 hours post-transfection for the remainder of the assay. 3) No light 
corresponds to siRNAs being transfected in HeLa cells in the absence of both UV and 































































Figure 3.16. Reduction in normalized firefly luciferase expression for siRNA 12 at 
160 and 800 pM in HeLa cells monitored 8 and 12 hours post-transfection. 1) UV 
corresponds to the siRNA being exposed under a 365nm UV lamp for inactivation prior to 
transfection. 2) Vis corresponds to the siRNA being exposed under a 365nm UV lamp for 
inactivation prior to transfection, however the transfected cells were exposed to a 13 W 
daylight lamp 4 hours post-transfection for the remainder of the assay. 3) No light 
corresponds to siRNAs being transfected in HeLa cells in the absence of both UV and 
visible light. Untreated control was co-transfected with both plasmids with no siRNA 
present. 
 
Figures 3.14-3.16 shows the remaining siRNAs with internally located Az2 spacer 
molecules.It appears as the Az2 linker moves towards the 3‘-end of the sense strand, that 
the trends start to normalize until siRNA 12, where each time point and each concentration 
makes have the same trend, where UV > Vis > No light treated cells. 
Introduction of azobenzene spacers causes significant destabilization in the siRNA 
duplex and the data supports that this destabilization can be utilized to create a spacially 
and temporally controlled siRNA through the azobenzene moiety in and around  the central 
region of the sense strand. These results look to be very promising, and work will likely 


















































4.0 Future Directions 
 These azobenzene siRNAs have proven to be effective RISC substrates, and further 
more exhibit excellent photochemical properties when exposed to light. These 
photochemical properties could be further explored in order make the siRNAs better 
pharmaceuticals. One such way would be to red-shift the trans to cis photo-isomerization 
out of the UV portion of the spectrum. UV light is toxic to cells and does not penetrate very 
far into biological tissues, which makes for a poor inactivation method in living subjects. 
Recent research has shown that it is possible to control the wavelengths that the N=N bond 
utilizes for photo-isomerization for in vivo applications by shifting the band from 330 nm 
to 530 nm resulting in thermally stable isomers.106  In a different study, Dong et al. 2015 
synthesized several azobenzene derivatives with peak absorbance well past the UV portion 
of the spectrum into the near red 600 nm range.107 They accomplished this by adding 
methoxy substituents at the four ortho positions flanking the N=N bond. This could be 
useful in transfection assays, since we would be able to expose the cell culture to the light 
indefinitely with little to no toxic effects. This would greatly improve temporal control of 
the siRNAs, but also open other avenues to explore that would not be possible with a UV 
light isomerization. 
 A second pathway of investigation would be to further test these azobenzene 
modifications for stability inside the cell. Many kinds of end cap provide nuclease 
resistance to siRNAs,3,42 but this one has the added functionality of being photo-
isomerizable. The effect of UV and visible light could be tested on these siRNAs to see if 
silencing efficacy is affected, or whether central region or 3’-end modifications show 




  Other possible investigative paths include adding multiple azobenzene 
modifications into a single sense strand to make it more effective at lower concentrations 
by causing multiple disruptions in the duplex, or cytotoxicity assays to determine the 
effects of high doses of siRNA on the cell population. Modification of the anti-sense strand 
instead of the sense strand to determine if incorporation into RISC is still possible.  More 
interesting possibilities include molecular modelling to see how these modifications affect 
the helix in both the cis and trans form, but also how they interact with bases and how 
favourable base stacking is, especially once ortho substitutions become a factor, bulking 
the molecule up and perhaps making it a poor substrate for RISC.  Finally, testing these 
siRNAs in a clinically relevant way, such as with the BCL-2 gene would open the door to 
not only treating cancer, but also many other types of endogenous targets to prevent or cure 
diseases. 
  Some challenges yet remain however. Because of the thermal instability of cis 
conformers, it can be difficult to find a switch that remains stable at physiological 
temperature. Azobenzenes can also be reduced under physiological conditions, so even if 









 This study presents a logical next step into the realm of photo-controlled siRNAs 
through central region azobenzene modifications. Shown here is the ability to inactivate 
and then re-activate siRNA activity through UV and visible light in order to provide a great 
deal of temporal control over mRNA expression through RISC. In addition to this, several 
siRNAs were shown to have IC50 very close to wild-type showing it could be possible to 
construct siRNAs with a low dose potential, reducing toxicity and off-target effects. 
Incorporation of these photo-switchable azobenzenes have incorporated several beneficial 
properties on these siRNAs: not just a photo tunable control for activity, but also 
applications in introducing site specific destabilization to strategically control which part 
of the siRNA we would like to inactivate. With several different azobenzene modifications 
that are controlled with different, specific wavelengths of light oligonucleotides could be 
the subject of site specific activation or inactivation at different times or in different 
locations. This would have widespread applicability in gene expression, transcriptional or 
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A1.1. 1H NMR Spectrum 4,4’-bis(hydroxyethyl)-azobenzene Compound (1) in DMSO-d6 





A1.2. 13C NMR Spectrum 4,4’-bis(hydroxyethyl)-azobenzene Compound (1) in DMSO-






A1.3. 1H NMR Spectrum 4,4’-bis(hydroxymethyl)-azobenzene Compound (2) in DMSO-





A1.4. 13C NMR Spectrum 4,4’-bis(hydroxymethyl)-azobenzene Compound (2) in 





A1.5. 1H NMR Spectrum 4-hydroxyethyl-4’-O-(4,4’dimethoxytrityl)-azobenzene  




A1.6. 13C NMR Spectrum 4-hydroxyethyl-4’-O-(4,4’dimethoxytrityl)-azobenzene  











A1.7. 1H NMR Spectrum 4-hydroxymethyl-4’-O-(4,4’dimethoxytrityl)-azobenzene 




A1.8. 13C NMR Spectrum 4-hydroxymethyl-4’-O-(4,4’dimethoxytrityl)-azobenzene 







A1.9. 1H NMR Spectrum of 2-Cyanoethyl-4-O-{[4-hydroxyethyl-4’-O-
(4,4’dimethoxytrityl)-O-methyl-diazenyl]}-N,N’-diisopropylaminophosphoramidite 






A1.10. 13C NMR Spectrum of 2-Cyanoethyl-4-O-{[4-hydroxyethyl-4’-O-
(4,4’dimethoxytrityl)-O-methyl-diazenyl]}-N,N’-diisopropylaminophosphoramidite 





A1.11. 31P NMR Spectrum of 2-Cyanoethyl-4-O-{[4-hydroxyethyl-4’-O-
(4,4’dimethoxytrityl)-O-methyl-diazenyl]}-N,N’-diisopropylaminophosphoramidite 






A1.12. 1H NMR Spectrum of  2-Cyanoethyl-4-O-{[4-hydroxymethyl-4’-O-
(4,4’dimethoxytrityl)-O-methyl-diazenyl]}-N,N’-diisopropylaminophosphoramidite 







A1.13. 13C NMR Spectrum of  2-Cyanoethyl-4-O-{[4-hydroxymethyl-4’-O-
(4,4’dimethoxytrityl)-O-methyl-diazenyl]}-N,N’-diisopropylaminophosphoramidite 




A1.14. 31P NMR Spectrum of  2-Cyanoethyl-4-O-{[4-hydroxymethyl-4’-O-
(4,4’dimethoxytrityl)-O-methyl-diazenyl]}-N,N’-diisopropylaminophosphoramidite 
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A1.15. Inhibitory response curves of siRNAs 7-13 and wt. 
 















































A1.17. Deconvolution results for siRNA 7. ESI-HRMS (ES+) m/z calculated for siRNA 7  







A1.18. Deconvolution results for siRNA 8. ESI-HRMS (ES+) m/z calculated for siRNA 8  







A1.19. Deconvolution results for siRNA 9. ESI-HRMS (ES+) m/z calculated for siRNA 9 






A1.20. Deconvolution results for siRNA 10. ESI-HRMS (ES+) m/z calculated for siRNA 












A1.21. Deconvolution results for siRNA 11. ESI-HRMS (ES+) m/z calculated for siRNA 









A1.22. Deconvolution results for siRNA 12. ESI-HRMS (ES+) m/z calculated for siRNA 







A1.23. Deconvolution results for siRNA 13. ESI-HRMS (ES+) m/z calculated for siRNA 
13 6410.89, found 6410.86 [M+H]+  
 
 

















A1.25. HPLC chromatogram for siRNA 9. Red no treatment, blue 60 min UV exposure. 
Arrows indicate trans and cis peaks and retention times. 
 
 
A1.26. HPLC chromatogram for siRNA 10. Red no treatment, blue 60 min UV exposure. 

























A1.27. HPLC chromatogram for siRNA 11. Red no treatment, blue 60 min UV exposure. 





A1.28. HPLC chromatogram for siRNA 12. Red no treatment, blue 60 min UV exposure. 
Arrows indicate trans and cis peaks and retention times. 
 
 
cis 
rt: 15.3 
 
trans 
rt: 16.0 
cis 
rt: 15.6 
 
trans 
rt: 16.3 
88 
 
 
